Pharma News
Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.
Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús
Friday, March 12, 2021Orgenesis Inc a global biotech company working to unlock the full potential of cell and gene therapies announces that it has entered the planned second phase of a collaboration with Hospital Infantil Universitario Nio Jess in Madrid Spain
Takeda Acquires Maverick Therapeutics to Advance T-Cell Activator Solid Tumor Treatments and Expand New Cancer Immunotherapy Portfolio
Thursday, March 11, 2021Takeda Pharmaceutical Company Limited announced the exercise of its option right to acquire Maverick Therapeutics Inc a privately held biopharmaceutical company pioneer in targeted and conditionally active bispecific Tcell immunotherapies
Complix Signs Global Drug Discovery and Development Agreement with I-Mab
Thursday, March 11, 2021Complix a biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with IMab Nasdaq IMAB an innovationdriven clinical stage biopharmaceutical company commi...
Sparta Biopharma Announces US Commercial Availability of BioEnthesis™ for Rotator Cuff Repair
Wednesday, March 10, 2021Sparta Biopharma Inc a privatelyheld company developing osteobiologics for sports medicine announces the availability of BioEnthesisTM the firstofitskind allograft that has both mineralized and demineralized layers which provide the requisite propert...
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
Wednesday, March 10, 2021NeuroRx Inc and TFF Pharmaceuticals Inc are announcing that the companies have entered into a feasibility and material transfer agreement Feasibility Agreement Under the Feasibility Agreement NeuroRx is delivering ZYESAMI aviptadil synthetic VIP mate...
Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes
Tuesday, March 09, 2021Eli Lilly and Company and Biolojic Design Ltd Biolojic a biotechnology company that computationally designs functional antibodies today announced a research collaboration and license agreement that will leverage Biolojics AIbased multibody platform t...
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
Tuesday, March 09, 2021Exelixis Inc and WuXi Biologics announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis oncology biologics pipeline The agreement is the latest in a series of biologicsfocused transactio...
Ridgeback Biotherapeutics and Merck Announce Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir
Monday, March 08, 2021Merck known as MSD outside the United States and Canada and Ridgeback Biotherapeutics LP announced preliminary results from Ridgebacks Phase a randomized doubleblind placebocontrolled trial to evaluate the safety tolerability
ABclonal Biotechnology Acquires Yurogen Biosystems to Better Serve Diagnostic and Pharmaceutical Researchers Worldwide
Saturday, March 06, 2021ABclonal Biotechnology Co Ltd a global life science tools and services provider acquires Yurogen Biosystems LLC a contract research organization dedicated to monoclonal antibody discovery using singleBcellbased SMabTM platform to better serve researc...
ConserV Bioscience and eTheRNA immunotherapies to Collaborate on Development of mRNA Vaccines for Infectious Diseases
Friday, March 05, 2021ConserV Bioscience Limited ConserV a clinicalstage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases and eTheRNA immunotherapies NV eTheRNA a clinicalstage immunotherapy company focused...
